Clario’s CEO: “This Partnership Accelerates Our Mission”
“This strategic transaction will power the continued expansion of Clario’s differentiated digital endpoint platform and proprietary suite of AI tools,” said Dr. Chris Fikry, Clario’s CEO. “Thermo Fisher’s global scale and deep ties with large pharma and biotech companies will fuel expansion of our clinical trial platform—benefiting our clients and, ultimately, patients.”
Building the Future of AI-Enabled Medicine
Thermo Fisher, which generates over $40 billion in annual revenue, continues to expand its reach into the biotech and healthcare data sectors. The Clario acquisition is expected to bolster its AI and analytics infrastructure at a pivotal time when pharmaceutical research is becoming increasingly data-driven.
With Thermo Fisher to acquire Clario, the partnership signals not just another corporate merger, but a leap forward in how the world’s most advanced medicines are developed, tested, and delivered—with speed, precision, and digital intelligence at the forefront.
